Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
Read More Drugs (Pharmaceuticals), Alzheimer’s Disease, Eli Lilly and Company, Food and Drug Administration, donanemab
